Literature DB >> 29210009

Influence of comorbidities on the implementation of the fundus examination in patients with newly diagnosed type 2 diabetes.

Taichi Kawamura1,2, Izumi Sato1,3, Hiroshi Tamura4,5,6, Yoko M Nakao7, Koji Kawakami8.   

Abstract

AIMS: To investigate the influence of comorbidities on undergoing a diabetic eye examination in patients with newly diagnosed type 2 diabetes mellitus (T2DM).
DESIGN: Retrospective cohort study
METHODS: This was a retrospective cohort study using data from health insurance claims made between January 2005 and March 2013 in Japan. The primary outcome was implementation of the fundus examination that includes fundus photography, ophthalmoscopy and optical coherence tomography by a doctor within one year of initial drug therapy for Type2 Diabetes Mellitus (T2DM). We used multivariable logistic regression models with adjustment for demographic parameters to investigate the influence of comorbidities (hypertension and/or hyperlipidemia) on patients with T2DM receiving fundus examinations. We conducted an additional analysis to investigate whether the site of treatment might influence the performance of fundus examinations in patients with T2DM.
RESULTS: A total of 6,492 patients were eligible for this analysis, of which 1,044 (16.1%) had comorbidities and 2,212 (34.1%) received the fundus examination. In the multivariable analysis, there was a significant association between comorbidities and a lower proportion of examination implementation (odds ratio [OR], 0.57; 95% confidence interval [CI], 0.48-0.68; P<0.001). The implementation proportion for patients treated for comorbidities and T2DM in the same facility was also low (OR, 0.52; 95% CI, 0.43-0.63; P<0.001).
CONCLUSIONS: These results suggest that the proportion of taking fundus examination is low among patients with comorbidities, especially in patients treated at the same facility for comorbidities and T2DM. This may help to increase the proportion of T2DM patients receiving fundus examinations.

Entities:  

Keywords:  Claims data; Comorbidity; Diabetes mellitus; Diabetic retinopathy; Eye examination

Mesh:

Year:  2017        PMID: 29210009     DOI: 10.1007/s10384-017-0551-8

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  42 in total

1.  Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program.

Authors:  E R Schoenfeld; J M Greene; S Y Wu; M C Leske
Journal:  Ophthalmology       Date:  2001-03       Impact factor: 12.079

2.  [Causes and prevalence of visual impairment in Japan].

Authors:  Rina Wako; Tsutomu Yasukawa; Aki Kato; Toyonori Omori; Susumu Ishida; Tatsuro Ishibashi; Yuichiro Ogura
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2014-06

Review 3.  Diabetic retinopathy: global prevalence, major risk factors, screening practices and public health challenges: a review.

Authors:  Daniel Shu Wei Ting; Gemmy Chui Ming Cheung; Tien Yin Wong
Journal:  Clin Exp Ophthalmol       Date:  2016-02-17       Impact factor: 4.207

Review 4.  Study of Global Health Strategy Based on International Trends: -Promoting Universal Health Coverage Globally and Ensuring the Sustainability of Japan's Universal Coverage of Health Insurance System: Problems and Proposals.

Authors:  Takashi Hatanaka; Narumi Eguchi; Mayumi Deguchi; Manami Yazawa; Masami Ishii
Journal:  Japan Med Assoc J       Date:  2015-09-01

5.  [Five years of changes in diabetic eye notebooks].

Authors:  Hideharu Funatsu; Sadao Hori; Toshimasa Fukuda; Takaichi Miyakawa; Naoto Yamaguchis
Journal:  Nippon Ganka Gakkai Zasshi       Date:  2010-02

6.  United Kingdom (England): Health system review.

Authors:  Seán Boyle
Journal:  Health Syst Transit       Date:  2011

7.  Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Authors:  A C Keech; P Mitchell; P A Summanen; J O'Day; T M E Davis; M S Moffitt; M-R Taskinen; R J Simes; D Tse; E Williamson; A Merrifield; L T Laatikainen; M C d'Emden; D C Crimet; R L O'Connell; P G Colman
Journal:  Lancet       Date:  2007-11-07       Impact factor: 79.321

8.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

Review 9.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

10.  Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.

Authors:  Harn-Shen Chen; Tzu-En Wu; Tjin-Shing Jap; Li-Chuan Hsiao; Shen-Hung Lee; Hong-Da Lin
Journal:  Diabetes Care       Date:  2008-06-12       Impact factor: 17.152

View more
  1 in total

1.  Sex Disparities in Cardiovascular Risk Factor Assessment and Screening for Diabetes-Related Complications in Individuals With Diabetes: A Systematic Review.

Authors:  Marit de Jong; Sanne A E Peters; Rianneke de Ritter; Carla J H van der Kallen; Simone J S Sep; Mark Woodward; Coen D A Stehouwer; Michiel L Bots; Rimke C Vos
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-30       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.